Vincristine sulfate CAS: 2068-78-2

CAS NO: 2068-78-2
Vincristine sulfate
Chemical Name: Vincristine sulfate
Molecular Formula: C46H58N4O14S
Formula Weight: 923.04
CAS No.: 2068-78-2
Description Review
Description

Vincristine sulfate is a naturally occurring antitumor alkaloid that is derived from the Madagascar periwinkle plant. It is one of the most commonly used chemotherapy agents in the treatment of various cancers, including leukemia, lymphoma, and breast cancer. Vincristine sulfate is often used in combination with other chemotherapy drugs to maximize its efficacy. It is administered intravenously and is available as a clear, colorless solution.

Chemical name:

Vincristine sulfate's chemical name is (3β,16β)-16-Ethyl-3-methoxy-2,3-dihydroindolizino[8,1-cd]carbazole-6-carboxamide sulfate (1:1).

Molecular formula:

The molecular formula of Vincristine sulfate is C46H56N4O10S.

Formula Weight:

The formula weight of Vincristine sulfate is 923.05 g/mol.

CAS No:

The CAS number of Vincristine sulfate is 2068-78-2.

Top Ten Keywords from Google and Synonyms:

  1. Chemotherapy
  2. Antitumor alkaloid
  3. Leukemia
  4. Lymphoma
  5. Breast cancer
  6. Oncology
  7. Vinca alkaloid
  8. Chemotherapy drug
  9. Cancer treatment
  10. Chemotherapy side effects

Synonyms:

Synonyms of Vincristine sulfate include:

• Vincristine • Oncovin • Leurocristine • Vincasar PFS • Vincrex • Vincosid • Vincristina

Health benefits of this product:

Vincristine sulfate has several potential health benefits, predominantly in the treatment of cancer. As an antitumor alkaloid, it can inhibit the growth and proliferation of cancer cells in various types of cancer, including leukemia, lymphoma, and breast cancer. In addition, Vincristine sulfate also has use as an immunosuppressant in the treatment of autoimmune diseases like rheumatoid arthritis.

Potential effects:

Vincristine sulfate can have several potential effects when used in chemotherapy treatment, including:

• Inhibiting the growth and proliferation of cancer cells • Inducing programmed cell death or apoptosis of cancer cells • Halting the process of cell division in cancer cells

When used as an immunosuppressant, Vincristine sulfate can help to reduce inflammation and joint pain in patients with autoimmune diseases.

Product mechanism:

Vincristine sulfate works by disrupting the microtubule structures within cells, which play a critical role in cell division. By interfering with microtubules, Vincristine sulfate can stop the process of cell division and induce apoptosis or programmed cell death. This process is crucial for slowing the growth and proliferation of cancer cells and can also contribute to the immunosuppressant qualities of Vincristine sulfate.

Safety:

Vincristine sulfate is a safe drug when administered appropriately and monitored by a medical professional. It is not recommended for use during pregnancy or nursing. Patients with liver or kidney disease should consult a doctor before using Vincristine sulfate.

Side effects:

The side effects of Vincristine sulfate can include:

• Nausea and vomiting • Fatigue and weakness • Hair loss • Constipation • Tingling and numbness in the extremities • Loss of deep tendon reflexes • Neutropenia or low white blood cell count • Increased risk of infection

Dosing information:

The dosing information for Vincristine sulfate should be determined by a healthcare professional. It is typically administered intravenously. The dose and frequency of Vincristine sulfate treatment will depend on the type and stage of cancer being treated.

Conclusion:

Vincristine sulfate is a highly effective chemotherapy drug derived from the Madagascar periwinkle plant. Its ability to disrupt the microtubule structures within cells can slow the growth and proliferation of cancer cells, making it widely used in the treatment of various types of cancer. Additionally, Vincristine sulfate is also used as an immunosuppressant in the treatment of autoimmune diseases. While it is a safe drug, patients should be closely monitored for side effects, including low white blood cell count and increased susceptibility to infection. The dosage of Vincristine sulfate should only be determined by a healthcare professional.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code